[wp-rss-aggregator template=”xoma-releases-full” source=”374″ pagination=”on”]
- March 12, 2026XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
- February 18, 2026XOMA Royalty to Present at Investor Conferences in March
- February 9, 2026XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
- January 12, 2026XOMA Royalty Announces CFO Transition
- December 30, 2025XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
- December 22, 2025XOMA Royalty Declares Quarterly Preferred Stock Dividends
- December 15, 2025XOMA Royalty Enters into Agreement to Acquire Generation Bio
- December 5, 2025XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
- November 21, 2025XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
- November 12, 2025XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
